Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05048082 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
A Phase 2 study of Lung Cancer, sponsored by OncoNano Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT05048082 is a Phase 2 study of Lung Cancer that has completed, run by OncoNano Medicine. The registered enrollment target is 24 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05048082, a Phase 2 study of Lung Cancer, has completed, sponsored by OncoNano Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This Phase 2 study is an open-label, single-arm trial where each patient is his/her own "intrapatient" control. All patients will receive a single dose of pegsitacianine prior to standard of care surgery.
Conditions Studied
Interventions
- DRUG pegsitacianine
- PROCEDURE Tumor resection surgery
Study Locations (2)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05048082
The ClinicalTrials.gov registry entry for NCT05048082 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is OncoNano Medicine, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pegsitacianine is the first listed.
NCT05048082 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT05048082 about?
NCT05048082 is a clinical study titled "A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies". This Phase 2 study is an open-label, single-arm trial where each patient is his/her own "intrapatient" control. All patients will receive a single dose of pegsitacianine prior to standard of care surgery.
What is the current status of trial NCT05048082?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2022-04-13. Estimated completion is 2022-08-31.
What conditions does trial NCT05048082 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT05048082?
The interventions under investigation include: pegsitacianine (DRUG), Tumor resection surgery (PROCEDURE).
Who is sponsoring clinical trial NCT05048082?
This trial is sponsored by OncoNano Medicine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05048082 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.